Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma

Allergy: European Journal of Allergy and Clinical Immunology, Supplement

Volumn 56, Issue 66, 2001, Pages 7-11

  Bisgaard, H ^a,b  

^a Mental Health Services CPH   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Asthma; Cysteinyl leukotrienes; Eosinophils; Exhaled nitric oxide; Inflammation; Leukotriene receptor antagonists; Montelukast

Indexed keywords

ACETYLSALICYLIC ACID; ALLERGEN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NITRIC OXIDE; PEPTIDOLEUKOTRIENE; PHOSPHOLIPID; PLACEBO; PRANLUKAST; ZAFIRLUKAST;

ASTHMA; BLOOD VESSEL PERMEABILITY; BRONCHOSPASM; CILIARY MOTILITY; CLINICAL TRIAL; COLD AIR; CONFERENCE PAPER; CORTICOSTEROID THERAPY; DRUG EFFECT; EOSINOPHILIA; EXERCISE TEST; HUMAN; MUCOCILIARY CLEARANCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; VASODILATATION;

EID: 0034965531     PISSN: 01081675     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2001.00002.x     Document Type: Conference Paper

References (34)

1. Cysteinyl leukotrienes in asthma: Old mediators up to new tricks
2. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases
3. 4 and histamine in exogenous asthma
4. 4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans
5. 4 in human skin
6. Leukotriene- and histamine-induced increases in vascular permeability and interstitial transport in the skin
7. 4, increase the release of mucus from human airways in vitro
8. SRS-A leukotrienes decrease the activity of human respiratory cilia
9. Eosinophils in asthma
10. 4 and granulocyte infiltration into asthmatic airways
11. Treatment of asthma with drugs modifying the leukotriene pathway
12. Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapy
13. 1 receptor
14. 4-induced bronchoconstriction in the human
15. 4 receptor antagonist ICI 204,219
16. Summary of clinical trials with zafirlukast
17. Montelukast reduces airway inflammation in asthma: A randomized, controlled trial
18. Bronchial biopsy specimen variability: Requirement for large sample size and repeated measurements to improve reliability
19. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist
20. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma
21. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial
22. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. A multicenter, randomized, double-blind trial
23. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction
24. Montelukast for chronic asthma in 6- to 14-year-old children
25. Increased nitric oxide in exhaled air of asthmatic patients
26. NO in exhaled air of asthmatic children is reduced by the leukotriene antagonist montelukast
27. 4 excretion
28. Effect of oral prednisone on airway inflammatory mediators in atopic asthma
29. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans
30. Montelukast added to inhaled beclomethasone in treatment of asthma
31. 4) receptor antagonist, in patients with chronic asthma
32. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without corticosteroids
33. Montelukast, a leukotriene receptor antagonist, provides additional clinical benefit in asthmatic children aged 6 to 14 years using inhaled corticosteroids
34. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients